Xeris Pharmaceuticals, Inc. forecast revenue between $380 million and $390 million [5] for fiscal year 2026.
The projection signals a period of aggressive growth for the company as it scales the commercial availability of its drug Recorlev. Management expects the expansion to ramp up during the second half of the year.
Recent financial data shows a strong start to the period. First-quarter net product revenue grew 43% to more than $82 million [1]. This increase was primarily fueled by Recorlev, which experienced 95% growth [2].
"First quarter net product revenue grew an impressive 43% to more than $82 million, driven by Recorlev, which nearly doubled with 95% growth, while Keveyis increased 4% and Gvoke remained flat year-over-year," John Shannon said.
While Recorlev dominates the growth trajectory, other products in the portfolio showed varying levels of stability. Keveyis saw a growth rate of four percent [3]. Meanwhile, Gvoke generated $20.8 million [4] in net revenue during the first quarter, remaining flat compared to the previous year.
The company is leaning on this momentum to meet its year-end targets. The anticipated surge in the second half of 2026 is tied directly to the broader commercial rollout of Recorlev, a key driver for the firm's updated financial guidance.
“Xeris Pharmaceuticals, Inc. forecast revenue between $380 million and $390 million for fiscal year 2026.”
The disparity in growth between Recorlev and other products like Gvoke suggests that Xeris is transitioning from a multi-product stability phase to a high-growth phase led by a single flagship asset. The company's ability to hit its $390 million target depends almost entirely on the successful execution of the Recorlev commercial expansion in the latter half of the year.
